The main endocrine drug treatments for prostate cancer are: luteinizing hormone-releasing hormone analogs, estrogens and anti-androgen drugs. They are described below. (1) Luteinizing hormone-releasing hormone analogue (LHRH-a) Luteinizing hormone-releasing hormone analogue is used for pharmacological debulking. Surgical debridement (removal of the testicles) can rapidly and consistently reduce the body’s androgen level to very low levels (i.e., debridement levels). However, surgical depot can cause psychological problems, so nowadays it is mostly used as a drug. Some of the drugs that have been marketed include leuprolide, goserelin, and treprostinil. Depending on the dosage form, the patient will be asked to have an injection every 1, 2, 3 or 6 months. After the initial injection of LHRH-a, androgens will gradually rise and begin to fall after 1 week, reaching depleted levels by 3 to 4 weeks. (2) Estrogens Estrogens can effectively inhibit androgen activity, etc. The most commonly used estrogen is ethylene estradiol, which can achieve the same effect as depot, but due to the high incidence of cardiovascular adverse effects of this drug, it must be applied with caution in clinical practice. (3) Anti-androgen drugs There are two major categories of anti-androgen drugs: one is steroidal drugs, represented by megestrol acetate; the other is non-steroidal drugs, mainly bicalutamide and flutamide. Anti-androgen drugs play a direct competitor to androgens in the body, and when androgens want to enter the cells of the prostate to work, they take over the androgen’s “job” first, making it useless in the prostate. The above briefly describes the endocrine drugs for prostate cancer, but there are also chemotherapy, immunotherapy, bone pain treatment drugs and so on. The actual choice of medication and treatment plan will be based on the actual condition of each patient, and the physician will make the most suitable individualized treatment plan.